![MiNK Therapeutics, Inc. logo](/logos/INKT.webp)
MiNK Therapeutics, Inc.
NASDAQ:INKT
Overview | Financials
Company Name | MiNK Therapeutics, Inc. |
Symbol | INKT |
Currency | USD |
Price | 0.788 |
Market Cap | 31,169,138 |
Dividend Yield | 0% |
52-week-range | 0.75 - 1.9 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jennifer S. Buell Ph.D. |
Website | https://minktherapeutics.com |
An error occurred while fetching data.
About MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD